Dohj LLC Sells 737 Shares of Biogen Inc. (NASDAQ:BIIB)

Dohj LLC reduced its position in shares of Biogen Inc. (NASDAQ:BIIB) by 7.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,753 shares of the biotechnology company’s stock after selling 737 shares during the period. Dohj LLC’s holdings in Biogen were worth $1,338,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. State Street Corp raised its holdings in Biogen by 3.5% during the 3rd quarter. State Street Corp now owns 7,344,960 shares of the biotechnology company’s stock worth $1,423,747,000 after purchasing an additional 248,942 shares during the last quarter. Geode Capital Management LLC raised its stake in Biogen by 1.3% during the third quarter. Geode Capital Management LLC now owns 3,613,020 shares of the biotechnology company’s stock worth $698,062,000 after buying an additional 47,055 shares during the last quarter. Pacer Advisors Inc. lifted its holdings in Biogen by 13,574.7% in the fourth quarter. Pacer Advisors Inc. now owns 2,667,531 shares of the biotechnology company’s stock valued at $407,919,000 after buying an additional 2,648,024 shares during the period. RA Capital Management L.P. boosted its position in Biogen by 20.6% during the third quarter. RA Capital Management L.P. now owns 1,184,456 shares of the biotechnology company’s stock valued at $229,595,000 after acquiring an additional 202,317 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Biogen by 1.7% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,152,691 shares of the biotechnology company’s stock worth $223,438,000 after acquiring an additional 18,905 shares during the period. 87.93% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

BIIB has been the subject of several research analyst reports. BMO Capital Markets lowered shares of Biogen from an “outperform” rating to a “market perform” rating and lowered their price objective for the company from $230.00 to $164.00 in a research note on Friday, December 20th. Barclays decreased their price objective on Biogen from $190.00 to $180.00 and set an “equal weight” rating for the company in a report on Thursday, October 31st. Citigroup lowered their price objective on Biogen from $190.00 to $160.00 and set a “neutral” rating for the company in a research note on Tuesday. Bank of America reaffirmed a “neutral” rating and issued a $178.00 target price on shares of Biogen in a report on Tuesday, December 10th. Finally, Oppenheimer reduced their price target on shares of Biogen from $270.00 to $255.00 and set an “outperform” rating for the company in a research report on Thursday, October 31st. Sixteen equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $228.80.

Biogen Stock Performance

Biogen stock opened at $143.93 on Friday. Biogen Inc. has a fifty-two week low of $139.71 and a fifty-two week high of $251.99. The stock has a market cap of $20.97 billion, a price-to-earnings ratio of 13.00, a PEG ratio of 1.66 and a beta of -0.07. The stock’s 50 day simple moving average is $150.79 and its two-hundred day simple moving average is $179.03. The company has a debt-to-equity ratio of 0.28, a quick ratio of 0.80 and a current ratio of 1.26.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $4.08 earnings per share for the quarter, topping the consensus estimate of $3.77 by $0.31. Biogen had a return on equity of 14.98% and a net margin of 16.81%. The company had revenue of $2.47 billion for the quarter, compared to analysts’ expectations of $2.43 billion. During the same period in the prior year, the firm earned $4.36 earnings per share. The firm’s revenue for the quarter was down 2.5% on a year-over-year basis. As a group, analysts expect that Biogen Inc. will post 16.43 earnings per share for the current fiscal year.

Biogen Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.